Logo

Celltrion Reports Results of CT-P10 (rituximab- biosimilar) in P-III for Advance Follicular Lymphoma (AFL)

Share this
Celltrion Reports Results of CT-P10 (rituximab- biosimilar) in P-III for Advance Follicular Lymphoma (AFL)

Celltrion Reports Results of CT-P10 (rituximab- biosimilar) in P-III for Advance Follicular Lymphoma (AFL)

Shots:

  • The study involves assessing efficacy and safety of CT-P10 vs Rituxan (rituximab) in 140 patients in ratio (1:1) with AFL for a duration of two years
  • P-III study results: @ 2 Year OS (93.2% vs 95.3%); PFS (75.2% vs 73.5%); relapse or disease progression (19.4% vs 21.3%); well tolerated and safe- Presented at ASH 2018
  • CT-P10 (rituximab- biosimilar) is a mAb for targeting CD20 cells and is approved in EU for NHL- chronic lymphocytic leukemia- RA- granulomatosis with polyangiitis and microscopic polyangiitis

Ref: Celltrion | Image: Celltrion


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions